ArticleInfection and drug resistance2026
Risk Stratification for Vancomycin-Associated Acute Kidney Injury in Chinese Adult Inpatients: A Multicenter Retrospective Cohort Study.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Vancomycin-associated acute kidney injury (VA-AKI) remains a major safety concern during treatment of serious infections. We aimed to identify a clinically relevant vancomycin trough threshold associated with VA-AKI and to define factors associated with renal injury in Chinese adult inpatients. Patients and Methods: We conducted a multicenter retrospective cohort study of 2230 Chinese adult inpatients treated with intravenous vancomycin between 2016 and 2025. VA-AKI was defined according to Kidney Disease: Improving Global Outcomes criteria. Receiver operating characteristic analysis was used to identify the trough threshold associated with VA-AKI, and multivariable logistic regression was performed to assess factors independently associated with VA-AKI. Results: VA-AKI occurred in 493/2230 patients (22.1%). The trough concentration most closely associated with VA-AKI was 15.9 mg/L (AUC 0.64). Compared with troughs <10 mg/L, concentrations of 10-20 mg/L and >20 mg/L were associated with progressively higher AKI risk. Factors independently associated with VA-AKI included contrast exposure, concomitant piperacillin-tazobactam or cephalosporin therapy, critical illness, treatment duration ≥14 days, cardiac dysfunction, and baseline renal impairment. VA-AKI was also associated with worse outcomes, including higher 60-day mortality (16% vs 4%) and greater dialysis requirement (6% vs 2%). Conclusion: In this large multicenter cohort, VA-AKI occurred in approximately one in five Chinese adult inpatients receiving vancomycin. A vancomycin trough concentration of approximately 15.9 mg/L may serve as a practical threshold for early AKI risk stratification, particularly in clinical settings where AUC-guided monitoring is not routinely available. Closer renal surveillance may be warranted in patients with additional treatment-related or clinical risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.